CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings.

Željko D TodorovicDusan TodorovicVladimir MarkovicNevena LadjevacNatasa ZdravkovicPredrag DjurdjevicNebojsa ArsenijevicMarija MilovanovicAleksandar ArsenijevicJelena Milovanovic

Published in: Current oncology (Toronto, Ont.) (2022)

Chimeric antigen receptor T (CAR T) cell therapy achieved remarkable success in B-cell leukemia and lymphoma which led to its incorporation in treatment protocols for these diseases. CAR T cell therapy for chronic lymphocytic leukemia (CLL) patients showed less success compared to other malignant tumors. In this review, we discuss the published results regarding CAR T cell therapy of CLL, possible mechanisms of failures and expected developments.

Keyphrases

cell therapy
chronic lymphocytic leukemia
stem cells
mesenchymal stem cells
end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
diffuse large b cell lymphoma
systematic review
combination therapy
patient reported
smoking cessation